Unmasking the anti-inflammatory cytokine response in rheumatoid synovitis

Rheumatology

Volumn 41, Issue 12, 2002, Pages 1341-1345

  Gerli, R ^c   Lunardi, C ^a   Pitzalis, C ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Ctr for the Stud of Rheum Dis   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD30 ANTIGEN; CHEMOATTRACTANT; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; EOTAXIN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; EDITORIAL; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; MEMORY CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVITIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

ANTIGENS, CD30; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CYTOKINES; HUMANS; INTERLEUKIN-10; INTERLEUKIN-4; RECEPTORS, CXCR4; SYNOVITIS; TH2 CELLS;

EID: 0036905662     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/41.12.1341     Document Type: Editorial

References (78)

1. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
2. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992; 35:729-34.
3. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis. Arthritis Rheum 1997;40:598-609.
4. Miossec P, van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997;40:2105-15.
5. Dolhain RJEM, Van der Heiden AN, Ter Haar NT, Breedveld FC, Miltenburg AMM. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996;9:1961-9.
6. Ying Z, Neure L, Grolms M et al. Th1/Th2 cytokine patterns in the joint of rheumatoid arthritis and reactive arthritis patients: analysis at the single cell level. Arthritis Rheum 1997;40:S37.
7. van der Graaf WL, Prins APA, Niers TMH, Dijkmans BAC, van Lier RAW. Quantitation of interferon gamma- and interleukin-4-producing T cells in synovial fluid and peripheral blood of arthritis patients. Rheumatology 1998;38:214-20.
8. Miltenburg AM, van Laar JM, de Kuiper R, Daha MR, Breedveld FC. T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand J Immunol 1992;35:603-10.
9. Quayle AJ, Choromat P, Miossec P, Kjeldsen-Kragh J, Forre O, Natvig JB. Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0-like) cytokine patterns. Scand J Immunol 1993; 38:75-82.
10. Morita Y, Yamamura M, Kawashima M et al. Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1669-76.
11. Firestein GS, Berger AE, Tracey DE et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 1992;149:1054-62.
12. Horai R, Saijo S, Tanioka H et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20.
13. Steiner G, Studnicka-Benke A, Witzmann G, Hofler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol 1995;22:406-12.
14. Miossec P, Naviliat M, Dupuy d'Angeac A, Sany J, Banchereau J. Low levels of interleukin-4 and high levels of transforming growth factor β in rheumatoid arthritis. Arthritis Rheum 1990;33:1180-7.
15. Bucht A, Larsson P, Weisbrot L et al. Expression of interferon-gamma (IFN-γ), IL-10, IL-12 and transforming growth factor-beta (TGF-β) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis. Clin Exp Immunol 1996; 103:357-67.
16. Isomäki P, Luukkainen R, Toivanen P, Punnonen J. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1693-702.
17. Cohen SBA, Katsikis PD, Chu C-G et al. High IL-10 production by the activated T cell population in the rheumatoid synovial membrane. Arthritis Rheum 1995; 38:946-52.
18. Yudoh K, Nakazawa F, Yonezawa T, Kimura T. Reduced expression of the regulatory CD4 + T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum 2000;43:617-27.
19. Joosten LAB, Lubberts E, Durez P et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997;40:249-60.
20. van Roon JAG, Lafeber FPJG, Bijlsma JWJ. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum 2001;44:3-12.
21. Suzuki N, Nakajiama A, Yoshino S, Matsushima K, Yagita H, Okumura K. Selective accumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritis. Int Immunol 1999;11:553-9.
22. Iezzi G, Scheidegger D, Lanzavecchia A. Migration and function of antigen-primed nonpolarized T lymphocytes in vivo. J Exp Med 2001;16:987-93.
23. Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 2001;22:41-7.
24. Morita Y, Yamamura M, Nishida K et al. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum 1999;41:306-14.
25. Yin Z, Siegert S, Neure L et al. The elevated ratio of interferon gamma/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology 1999;38:1058-67.
26. Van Roon JAG, Glaudemans CAFM, Lafeber FPJG, Bijlsma JWJ. Generation of suppressive Th2 cells from rheumatoid arthritis patients using IL-7 and IL-4 [abstract]. Arthritis Rheum 1999;42(Suppl. 9):S94.
27. Davis LS, Cush JJ, Schulze-Koops H, Lipsky PE. Rheumatoid synovial CD4+ T cells exhibit a reduced capacity to differentiate into IL-4-producing T-helper-2 effector cells. Arthritis Res 2001;3:54-64.
28. Kanegane H, Kasahara Y, Niida Y et al. Expression of L-selectin (CD62L) discriminates Th1- and Th2-like cytokine-producing memory CD4+ T cells. Immunology 1996;87:186-90.
29. De Jong R, Brouwer M, Hoolbrink B, van der PouwKraan T, Miedema F, van Lier RAW. The CD27- subset of peripheral blood memory CD4 + lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur J Immunol 1992;22:993-9.
30. Tortorella C, Schulze-Koops H, Thomas R et al. Expression of CD45RB and CD27 identifies subsets of CD4 + memory T cells with different capacities to induce B cell differentiation. J Immunol 1995;155:149-62.
31. Davis LS, Oppenheimer-Marks N, Schulze-Koops H, Lipsky PE. Th1/Th2 cytokine balance in arthritis: comment on the article by Miossec and van den Berg. Arthritis Rheum 1998;41:1896-7.
32. Annunziato F, Cosmi L, Galli G et al. Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in vivo. J Leukoc Biol 1999; 65:691-9.
33. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR5 by human T helper cells. Science 1997;277:2005-7.
34. Qin S, Rottman JB, Myers P et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998;101:746-54.
35. Zingoni A, Soto O, Hedrick JA et al. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol 1998;161:547-51.
36. Scotet E, Schroeder S, Lanzavecchia A. Molecular regulation of CC-chemokine receptor 3 expression in human T helper 2 cells. Blood 2001;15:2568-70.
37. Annunziato F, Galli G, Romagnani P et al, Chemokine receptors and other surface molecules preferentially associated with human Th1 or Th2 cells. Microbes Infect 1999; 1: 103-6.
38. Nanki T, Lipsky PE. Lack of correlation between chemokine receptor and Th1/Th2 cytokine expression by individual memory T cells. Int Immunol 2000; 12:1659-67.
39. Nagata K, Tanaka K, Ogawa K et al. Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol 1999;162:1278-86.
40. Nagata K, Hirai H, Tanaka K et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett 1999;459:195-9.
41. Cosmi L, Annunziato F, Iwasaki M et al. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur J Immunol 2000;30:2972-9.
42. Mossman TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-57.
43. Cohen S. Cytokine profile data. Immunol Today 2000;3:199.
44. Galli G, Annunziato F, Mavilia C et al. Enhanced HIV expression during Th2 oriented responses explained by the opposite regulatory effect of IL-4 and IFN-γ, on fisin/CXCR4. Eur J Immunol 1998;28:3280-90.
45. Nanki T, Hayashida K, El Gabalawy HS et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4(+) T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000; 165:6590-8.
46. Buckley CD, Amft N, Bradfield PF et al. Persistent induction of the chemokine receptor CXCR4 by TGF-beta1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 2000; 165:3423-9.
47. Falini B, Pileri S, Pizzolo G et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85:1-14.
48. + T cells by IL-4 and IFN-γ. J Immunol 1997;158:2090-8.
49. + T cells producing Th2-type cytokines. FASEB J 1995;9:81-6.
50. + T cells. J Immunol 1993; 151:2380-9.
51. Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1 positive tumor-cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 1989;19:157-62.
52. Nadali G, Vinante F, Stein H et al. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol 1995;13:1355-60.
53. Del Prete G, Maggi E, Pizzolo G, Romagnani S. CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today 1995;16:76-80.
54. Caligaris-Cappio F, Bertero MT, Converso M et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995;13:339-43.
55. Chilosi M, Facchetti F, Notarangelo LD et al. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome. Evidence for a Th2-mediated condition. Eur J Immunol 1996;26:329-34.
56. Leonard C, Tormey V, Faul J, Burke CM, Poulter LW. Allergen-induced CD30 expression on T cells of atopic asthmatics. Clin Exp Allergy 1997;27:780-6.
57. Giacomelli R, Cipriani P, Lattanzio R et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997; 108:42-6.
58. Mavilia C, Scaletti C, Romagnani P et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997;151:1751-8.
59. D'Elios MM, Romagnani P, Scaletti C et al. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J Leukoc Biol 1997; 61:539-44.
60. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997;18:263-6.
61. + T cell involvement in the inflamed joints. Clin Exp Immunol 1995;102:547-50.
62. + cells are induced by Mycobacterium tuberculosis and present in tuberculosis lesions. Int Immunol 1997;9:713-20.
63. Wang G, Hansen H, Tatsis E, Csernok E, Lemke H, Gross WL. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 1997;102:517-23.
64. Okumura M, Hidaka Y, Kuroda S, Takeoka K, Tada H, Amino N. Increased serum concentrations of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 1997;82:1757-70.
65. Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM. Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol 1996;80:311-20.
66. Gerli R, Caligaris-Cappio F, Bistoni O, Bertero MT, Giacomelli R, Falini B. Soluble CD30 in primary Sjögren's syndrome. Clin Exp Rheumatol 1999;17:389-90.
67. Gerli R, Bistoni O, Lunardi C et al. Soluble CD30 in early rheumatoid arthritis as predictor of good response to second line therapy. Rheumatology 1999;38:1282-4.
68. + T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol 2000;164:4399-407.
69. Gerli R, Lunardi C, Vinante F, Bistoni O, Pizzolo G, Pitzalis C. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2001;22:72-7.
70. Dechanet J, Merville P, Durand I, Banchereau J, Miossec P. The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium. J Clin Invest 1995;95:456-63.
71. Perez L, Orte J, Brieva JA. Terminal differentiation of spontaneous rheumatoid factor-secreting B cells from rheumatoid arthritis patients depends on endogenous interleukin-10. Arthritis Rheum 1995;38:1771-6.
72. Al Janadi M, al Dalaan A, al Balla S, al Humaidi M, Razziudin S. Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis. J Clin Immunol 1996;16:198-207.
73. Cañete JD, Martinez SE, Farrés J et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon γ is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis 2000;59:263-8.
74. Rudwaleit M, Yin Z, Siegert S et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumor necrosis factor a, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis 2000;59:311-4.
75. Huizinga TWJ, Keijsers V, Yanni G et al. Are differences in interleukin 10 production associated with joint damage? Rheumatology 2000;39:1180-8.
76. Taylor PC, Williams RO, Maini RN. Immunotherapy for rheumatoid arthritis. Curr Opin Immunol 2001;13:611-6.
77. Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheum 2000;43:2383-90.
78. Pisetsky DS. Tumor necrosis factor α blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 2000;43:2381-2.